Lung Cancer Clinical Trials in Pittsburgh

Showing 341-360 of 684 trials

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).

Non-Small Cell Lung CancerOvarian CancerFallopian Tube Cancer+3 more

Kite, A Gilead Company16 participantsStarted Oct 2019

Phoenix, Arizona, United States • Los Angeles, California, United States • Tampa, Florida, United States +7 more locations

COMPLETEDPhase 2< 1 mile

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

NCT02879617

This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).

Non-Small Cell Lung Cancer NSCLC

Academic Thoracic Oncology Medical Investigators Consortium47 participantsStarted Apr 2017

Pittsburgh, Pennsylvania, United States • Dallas, Texas, United States

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Lung Cancer Trials in Other Cities

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of PRT2527 in Participants With Advanced Solid Tumors

The Lung Screening, Tobacco and Health Project

Prospective Clinicogenomic Program

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Lung EpiCheck Biomarkers Development Study

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in Pittsburgh